MN-DIGI-INTL
15.6.2021 15:02:07 CEST | Business Wire | Press release
Digi International (NASDAQ: DGII) (www.digi.com ), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the expansion of its market-leading ConnectCore® family of products with the introduction of the Digi ConnectCore® 8M Mini System on Module (SOM).
Digi ConnectCore 8M Mini is a highly integrated and cost-effective SOM platform based on the NXP® i.MX 8M Mini applications processor. Featuring the optimal balance of performance, power and cost, it’s designed for mission-critical industrial, medical, transportation and agriculture applications. Digi ConnectCore simplifies embedded product development thanks to integrated memory, power management, pre-certified wireless, advanced security and the complete, open-source Digi Embedded Yocto Linux software platform based on Yocto Project™ or Android-based Digi Embedded Android, setting the product apart and enabling manufacturers to get to market faster with lower risk and cost and to focus on their core competency.
“Digi is excited to be expanding the Digi ConnectCore® family of products," said Steve Ericson, General Manager, OEM Solutions at Digi International. "We remain dedicated to delivering advanced solutions that simplify product development for manufacturers seeking secure, connected products that also help reduce the cost of R&D. The Digi ConnectCore 8M Mini SOM extends that commitment and delivers increased capability while lowering the total cost of ownership.”
With versatile, power-efficient ARM® Cortex® -A53 and Cortex-M4 processing cores, rich multimedia (2D/3D GPU, VPU, MIPI-DSI/CSI, SAI, PDM) and advanced connectivity (802.11 ac, Bluetooth 5, Gigabit Ethernet), the Digi ConnectCore 8M Mini is ideal for Internet of Things (IoT), human-machine interface (HMI), equipment monitoring, audio/voice, edge computing and machine learning applications.
Security and longevity are at the heart of the Digi ConnectCore 8M Mini’s design. Digi TrustFence® delivers a tested and fully integrated device security framework designed for the long product life cycle of embedded devices. Additionally, the i.MX 8M Mini processor is industrial qualified and backed by NXP’s Product Longevity Program, ensuring long-term availability of 10-plus years.
The Digi ConnectCore 8M Mini’s feature set makes it the only SOM among its competitors to offer Bluetooth 5 compatibility and cellular enablement, as well as Digi’s proprietary TrustFence security framework. At 40 x 45 x 3.5 mm, its physical hardware size is also among the smallest in the industry. Access a full list of additional Digi 8M Mini features here .
Availability
Initial Digi ConnectCore 8M Mini development kits and software will be available through global distribution partners June 15, 2021.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005035/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom